CClinicalTrials.gg
CompletedNCT03445572Updated Aug 6, 2020

Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer

An interventional study of Best Practice and Meditation Therapy in Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-06.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial studies how well meditative slow breathing or Isha Kriya meditation works in improving cancer-related symptoms in hospitalized participants with cancer. Meditative slow breathing or Isha Kriya meditation may help to decrease perceived stress and enhance well-being in hospitalized cancer participants.

Read the detailed description

PRIMARY OBJECTIVES:

I. Test the feasibility of the meditation practice.

SECONDARY OBJECTIVES:

I. Explore the acceptability of meditation in cancer patients through modified Global Symptom Evaluation (GSE) and on day 7 +/- 1 day and day 28 +/- 3 days.

II. Explore the effect of meditative practices in cancer patients through Edmonton Symptom Assessment Scale (ESAS) on the day of enrolment and a weekly basis until the end of study at four weeks.

OUTLINE: Participants are randomized to 1 of 3 groups.

GROUP I (MSB): Participants are instructed on the meditative slow breathing (MSB) technique and then perform MSB over 15 minutes twice daily (BID) for 28 days.

GROUP II (IK MEDITATION): Participants are instructed on the 3 steps of Isha Kriya (IK) meditation and then perform IK meditation over 15 minutes BID for 28 days.

GROUP III (WAITLIST): Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of malignancy
  • Admitted to the hospital
  • Able to follow instructions
  • Eastern Cooperative Oncology Practice (Eastern Cooperative Oncology Group [ECOG]) score of 3 or below
  • Fluency in English

Exclusion criteria

Exclusion Criteria:

  • Patients with life expectancy less than 2 months per attending physician or advance practice provider's note or assessment of prognosis
  • Patients with cognitive dysfunction
  • Patients who are admitted for observation for \< 48 hours will be excluded from the study, as one day would be difficult to provide the necessary information
  • Patients who are delirious
  • Patients who are unable to follow instructions due to their medical condition
  • Patients admitted to the intensive care unit
  • Patients with ESAS > 4/10 on dyspnea
  • Patients requiring oxygen more than 2 liters
  • Patients who are current meditation practitioners
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Group I (MSB)

    Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.

    Procedure: Meditation Therapy · Other: Questionnaire Administration

  • Experimental
    Group II (IK meditation)

    Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.

    Procedure: Meditation Therapy · Other: Questionnaire Administration

  • Active comparator
    Group III (waitlist)

    Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.

    Other: Best Practice · Other: Questionnaire Administration

Interventions

  • OtherBest Practice

    Receive standard supportive care

    Also known as: standard of care, standard therapy

  • ProcedureMeditation Therapy

    Perform MSB

    Also known as: Meditation

  • ProcedureMeditation Therapy

    Perform IK meditation

    Also known as: Meditation

  • OtherQuestionnaire Administration

    Ancillary studies

05

What researchers measure

Primary outcomes

  1. Feasibility of the Meditation Practice defined by Recruitment Rate

    Time frame: Day 7

  2. Feasibility of the Meditation Practice defined by Adherence Rate

    Time frame: Day 7

Secondary outcomes

  1. Acceptability of Meditation in Cancer Patients Assessed by Modified Global Symptom Evaluation (GSE)

    Time frame: Day 7 and Day 28

  2. Effect of Meditative Practices in Cancer Patients Assessed by Edmonton Symptom Assessment Scale (ESAS)

    Scale is from 0 to 10 with 0 being no symptoms to 10 being worse symptoms. Proportions of participants who consider that the study makes their symptoms better estimated along with a 90% confidence interval for each of the intervention groups. The Linear mixed model used to examine the differential changes over time for ESAS scores among the three groups.

    Time frame: Enrollment and a weekly basis until the end of study at four weeks.

06

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
07

References and documents

Publications

  • Narayanan S, Reddy A, Lopez G, Liu W, Wu J, Liu D, Manzano J, Williams JL, Mallaiah S, George M, Amaram J, Subramaniam B, Cohen L, Bruera E. Randomized Feasibility Study of Meditative Practices in Hospitalized Cancer Patients. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420909903. doi: 10.1177/1534735420909903. PubMed 32153208 ↗
08

Registry details

Key details

Study ID
NCT03445572
Lead sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Sep 21, 2018
Primary completion
Aug 4, 2020
Completion
Aug 4, 2020
Last update
Aug 6, 2020

Study contacts

Santhosshi Narayanan
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion